Gene Expression Analysis Reveals Distinct Pathways of Resistance to Bevacizumab in Xenograft Models of Human ER-Positive Breast Cancer

Bevacizumab, the recombinant antibody targeting vascular endothelial growth factor (VEGF), improves progression-free but not overall survival in metastatic breast cancer. To seek further insights in resistance mechanisms to bevacizumab at the molecular level, we developed VEGF and non-VEGF-driven ER...

Descripción completa

Detalles Bibliográficos
Autores principales: Gökmen-Polar, Yesim, Goswami, Chirayu P., Toroni, Rachel A., Sanders, Kerry L., Mehta, Rutika, Sirimalle, Usha, Tanasa, Bogdan, Shen, Changyu, Li, Lang, Ivan, Mircea, Badve, Sunil, Sledge Jr, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2014
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142325/
https://www.ncbi.nlm.nih.gov/pubmed/25157274
http://dx.doi.org/10.7150/jca.8466

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4142325/
https://www.ncbi.nlm.nih.gov/pubmed/25157274
http://dx.doi.org/10.7150/jca.8466

Ejemplares similares